GROWTH

Maximize portfolio value & deliver new product launches

Immunoglobulin sales up by 11%^# on the prior comparable period.

IDELVION®, recombinant coagulation factor for the treatment of haemophilia B, sales exceeded forecast and is the market leader in a number of countries.

Specialty products portfolio grew by 24%^# driven by strong performance in KCENTRA® and HAEGARDA®, which achieved nearly 50% of the prophylaxis hereditary angioedema (HAE) market in the United States (US).

Exercised the option to acquire 100% of Chinese plasma fractionator.

EFFICIENCY

Be the most efficient, highest quality plasma player

CSL Plasma opens 27 new collection centres in the US – a growth rate unmatched in the industry. Across the US and Europe, CSL Plasma now holds more than 200 collection centres.

Launch of a new CSL Plasma donor management system.

Investments in large-scale Group-wide capital initiatives, across all regions, remain on track.

INFLUENZA

Delivery on influenza strategy

Seqirus delivers on its commitment to achieve profitability just three years after the business was formed.

Influenza sales grew 53%^#, with FLUAD, an adjuvanted influenza vaccine, reporting sales up by 142%^#.

The Holly Springs facility in the US, which utilises innovative cell-based technology, quadrupled the number of FLUCELVAX® QUADRIVALENT influenza vaccine doses for the US market.

INNOVATION

Pursue new opportunities to diversify portfolio and enhance growth

Approval of immunoglobulin products PRIVIGEN®, in the US, and HIZENTRA®, in the US and Europe, provides patients with a convenient treatment for chronic inflammatory demyelinating polyneuropathy (CIDP).

Acquisition of Calimmune provides CSL with a promising gene therapy platform.

CSL and Vitaeris announce strategic partnership to support an emerging transplant portfolio.

CSL112, our cardiovascular disease product, moves into Phase III clinical trial.

PEOPLE & CULTURE

Create a culture that attracts, retains and develops the best talent

Named one of the world’s Top 50 employers by Forbes (2017) Global 2000: World’s Best Employers.

Total workforce continues to grow, achieving employee engagement index scores higher than the global IBM norms.

New people manager programs launched to develop skills and capabilities at every stage of their career.